PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 24, 2024Advances in Therapy20 citationsOpen Access

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

View Full Paper

Authors

HEHermann EinselePMPhilippe MoreauNBNizar J. Bahlis

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Einsele et al. (2024) studied this question.

synapsesocial.com/papers/68e77b43b6db6435876eff13https://doi.org/10.1007/s12325-024-02797-x
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( <scp>RRMM</scp> ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis2026 · 2 citations
  2. 2Unlocking hope: talquetamab in multiple myeloma treatment: a bispecific breakthrough targeting CD3 and GPRC5D2024
  3. 3Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-12025 · 15 citations
  4. 4P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS2026
  5. 5Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.2024 · 1 citations